» Articles » PMID: 17671187

Enhanced Peritoneal Ovarian Tumor Dissemination by Tissue Transglutaminase

Overview
Journal Cancer Res
Specialty Oncology
Date 2007 Aug 3
PMID 17671187
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Tissue transglutaminase (TG2) is involved in Ca(2+)-dependent aggregation and polymerization of proteins. We previously reported that TG2 mRNA is up-regulated in epithelial ovarian cancer (EOC) cells compared with normal ovarian epithelium. Here, we show overexpression of the TG2 protein in ovarian cancer cells and tumors and its secretion in ascites fluid and define its role in EOC. By stable knockdown and overexpression, we show that TG2 enhances EOC cell adhesion to fibronectin and directional cell migration. This phenotype is preserved in vivo, where the pattern of tumor dissemination in the peritoneal space is dependent on TG2 expression levels. TG2 knockdown diminishes dissemination of tumors on the peritoneal surface and mesentery in an i.p. ovarian xenograft model. This phenotype is associated with deficient beta(1) integrin-fibronectin interaction, leading to weaker anchorage of cancer cells to the peritoneal matrix. Highly expressed in ovarian tumors, TG2 facilitates i.p. tumor dissemination by enhancing cell adhesion to the extracellular matrix and modulating beta(1) integrin subunit expression.

Citing Articles

PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives.

Vorderbruggen M, Velazquez-Martinez C, Natarajan A, Karpf A Int J Mol Sci. 2024; 25(10).

PMID: 38791105 PMC: 11121112. DOI: 10.3390/ijms25105067.


Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2).

Valdivia A, Vagadia P, Guo G, OBrien E, Matei D, Schiltz G J Med Chem. 2023; 66(14):9445-9465.

PMID: 37449845 PMC: 10388319. DOI: 10.1021/acs.jmedchem.2c01859.


Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines.

Atobatele A, Tonoli E, Vadakekolathu J, Savoca M, Barr M, Kataria Y Cell Death Dis. 2023; 14(5):317.

PMID: 37160910 PMC: 10170068. DOI: 10.1038/s41419-023-05818-9.


TGM2 inhibits the proliferation, migration and tumorigenesis of MDCK cells.

Qiu Z, Guo S, Liu G, Pei M, Liao Y, Wang J PLoS One. 2023; 18(4):e0285136.

PMID: 37115802 PMC: 10146566. DOI: 10.1371/journal.pone.0285136.


The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.

Chen X, Adhikary G, Newland J, Xu W, Ma E, Naselsky W Mol Carcinog. 2022; 62(1):90-100.

PMID: 35848131 PMC: 9771885. DOI: 10.1002/mc.23446.